Add this topic to your myFT Digest for news straight to your inbox
Bristol-Myers Squibb’s $90bn takeover sets stage for big pharma M&A in 2019
Cash-and-stock offer ranks as one of biggest ever pharma deals
Discordant notes expected at this year’s Asco, a kind of rock festival for pharma
Clinical setbacks in cancer research are likely to be punished
Scientists are seeking combination drugs that would make for more effective treatments
Drugmaker to pay Nektar $1.85bn upfront in hope of boosting cancer immunotherapies
US drugmaker hails breakthrough as it reports rising revenues but suffers US tax hit
Pharma company sees success in lung cancer treatment study
US drugmaker looks at ‘strategic alternatives’ for over-the-counter medicines unit
Swedish retailer shows the value of snapping up a venture-backed companies
From astrophysicists to entrepreneurs, technology leads drugmakers to seek new skills
With almost 800 trials under way observers warn scientific rigour is being compromised
Doctors have to act as financial planners to find treatment that patients can afford
Scientific advances and legal incentives have encouraged investment
Do not write pharma group’s obituary as an independent company just yet
Deal with Jana Partners to appoint three new directors amid search for new chief
Investors lose billions as immunotherapies fall short of high expectations
International Edition